UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-QSB
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended March 31, 2005
Commission File No. 33-55254-28
INNOVATE ONCOLOGY, INC.
-----------------------
(Exact name of registrant as specified in its charter)
NEVADA 87-0438641
(State or other jurisdiction of (IRS Employer Identification No.)
incorporatin or organization)
712 Fifth Avenue, 19 th Floor New York, NY 10019
------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number including area code: (646) 723-8944
--------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
The number of shares outstanding of the registrant's common stock, par value
$0.001, as of May 6, 2005, was 17,953,242.
Innovate Oncology, Inc
Form 10-QSB for the quarter ended March 31, 2005
Index
Page
Part I
Item 1. Financial Statements 3
Item 2. Management Discussion and Analysis or Plan of Operation 9
Item 3. Controls and Procedures 16
Part II
Item 1. Legal Proceedings 16
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 16
Item 3. Default on Senior Securities 16
Item 4. Submission of Matters to a Vote of Security Holders 16
Item 5. Other Information 16
Item 6. Exhibits and Reports on Form 8-K 16
Signatures 17
2
INNOVATE ONCOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEET
March 31,2005
(Unaudited)
ASSETS
$ 0
------------
0
------------
$ 0
============
LIABILITIES AND STOCKHOLDERS' (DEFICIT)
CURRENT LIABILITIES
Accrued expenses $ 45,000
Due to related parties 100,000
Notes payable to related parties 2,696,754
-----------
TOTAL LIABILITIES 2,841,754
-----------
Commitments and Contingencies 0
STOCKHOLDERS' (DEFICIT)
Preferred stock, $.001 par value;
authorized 25,000,000 shares;
none issued 0
Common stock, $.001 par value;
authorized 125,000,000 shares;
17,953,242 issued and outstanding 17,953
Additional paid in capital (17,953)
Accumulated deficit during development stage (2,841,754)
-----------
TOTAL STOCKHOLDERS' (DEFICIT) (2,841,754)
-----------
$ 0
===========
The accompanying notes are an integral part of these financial statements.
3
INNOVATE ONCOLOGY, INC
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months From Inception
Ended (July 21, 2004)
March 31, to March 31,
2005 2005
EXPENSES
General and Administrative $ 284,370 511,775
Research and Development 1,437,347 2,329,979
----------------------------
NET LOSS (1,721,717) (2,841,754)
TOTAL COMPREHENSIVE (LOSS) $ (1,721,717) (2,841,754)
============================
Net (Loss) Per Common Share, Basic and Diluted $ (0.10)
============
Weighted Average Number of Shares Outstanding 17,953,243
============
The accompanying notes are an integral part of these financial statements.
4
INNOVATE ONCOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' (DEFICIT)
(Unaudited)
ADDITIONAL TOTAL
PAID IN ACCUMULATED STOCKHOLDERS
COMMON STOCK CAPITAL DEFICIT DEFICIT
SHARES AMOUNT
Initial capitalization 1,453,242 $ 1,453 (1,453) $
Shares issued in reorganization 16,500,000 16,500 (16,500)
October 01, 2004
Net loss (1,120,037) (1,120,037)
----------- -------------------------- ----------- ------------
Balance December 31, 2004 17,953,242 17,953 (17,953) (1,120,037) $ (1,120,037)
Net loss (1,721,717) (1,721,717)
----------- -------------------------- ----------- ------------
Balance March 31, 2005 17,953,242 $ 17,953 (17,953) (2,841,754) (2,841,754)
========== ========================== =========== ============
The common shares have been adjusted to reflect the 3.8 to 1 reverse share split
and the cancellation of 5,026,590 shares initial capitalization.
The accompanying notes are an integral part of these financial statements.
5
INNOVATE ONCOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months to From Inception,
March,31 2005 July 21, 2004, to
March 31, 2005
--------------- -----------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) $ (1,721,717) $ (2,841,754)
Adjustments to reconcile net (loss) to
net cash (used) in operating activities
Accrued expenses 10,000 45,000
Amount due to related party 30,000 100,000
Changes in other assets 42,106 0
--------------- -----------------
NET CASH (USED) IN OPERATING ACTIVITIES (1,639,611) (2,696,754)
--------------- -----------------
CASH FLOWS FROM INVESTING ACTIVITIES 0 0
--------------- -----------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Note payable to related party $ 1,639,611 $ 2,696,754
--------------- -----------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 1,639,611 2,696,754
--------------- -----------------
NET INCREASE IN CASH AND CASH EQUIVALENTS 0 0
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD 0 0
--------------- -----------------
CASH AND CASH EQUIVALENTS AT
END OF PERIOD $ 0 $ 0
=============== =================
SUPPLEMENTAL DISCLOSURE OF CASH
FLOW INFORMATION
Cash paid during year for:
Interest 0 0
=============== =================
Taxes 0 0
=============== =================
The accompanying notes are an integral part of these financial statements.
6
INNOVATE ONCOLOGY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31,2005
(Unaudited)
NOTE 1 - Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and pursuant to the rules and regulations of the
Securities and Exchange Commission. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. The financial statements should be read in
conjunction with the financial statements and notes thereto included in the
Innovate Oncology, Inc. (the "Company") Annual Report on Form 10-KSB for the
year ended December 31, 2004. The material under the heading "Management's
Discussion and Analysis or Plan of Operation" is written with the presumption
that the readers have read or have access to the 2004 Annual Report on Form
10-KSB, which contains Management's Discussion and Analysis or Plan of Operation
as of December 31, 2004 and for the period then ended.
In the opinion of management, the unaudited financial statements contain all
adjustments, consisting only of normal recurring adjustments, necessary for a
fair statement of the balance sheet and stockholders' equity as of March 31,
2005 and the statements of earnings and cash flows for the three month period
ended March 31, 2005. The results of operations for the three month period ended
March 31, 2005 are not necessarily indicative of the results of operations to be
expected for the entire fiscal year ending December 31, 2005.
NOTE 2 - Going Concern
The accompanying consolidated financial statements have been prepared on the
basis of accounting principles applicable to a going concern, which assume that
the Company will continue in operation for at least one year and will be able to
realize its assets and discharge its liabilities in the normal course of
operations. However, as of December 31, 2004, the Company did not have
significant cash or other material assets, nor did it have an established source
of revenues sufficient to cover its operating costs and allow it to continue as
a going concern. The Company is presently entirely dependent for its capital
requirements on a credit facility of $5 million advanced by its major
shareholder, Bioaccelerate Holdings, Inc. (Bioaccelerate). The Company's future
capital requirements will depend upon numerous factors including, but not
limited to, continued progress in developing its products, market penetration
and profitable operations from the sale of its products. These financial
statements do not reflect adjustments that would be necessary if the Company
were unable to continue as a going concern. While members of the Company's
management have been successful in raising capital for other ventures in the
past, and plan to raise equity capital for the Company, there can be no
assurance that these plans will be achieved on acceptable terms.
NOTE 3 - Stock Based Compensation
The Company has elected to adopt the disclosure only provisions of SFAS No. 148
and will continue to follow APB Opinion No. 25 and related interpretations in
accounting for stock options granted to its employees and directors.
Accordingly, employee and director compensation expense is recognized only for
those options whose price is less than the market value at the measurement date.
When the exercise price of the employee or director stock options is less then
the estimated fair value of the underlying stock on the grant date, the Company
records deferred compensation for the difference and amortizes this amount to
expense in accordance with FASB Interpretation No. 28, Accounting for Stock
Appreciation Rights and Other Variable Stock Options or Award Plans, over the
vesting period of the options. No options have been granted to date.
Stock options and warrants issued to non-employees are recorded at their fair
value as determined in accordance with SFAS No. 123 and Emerging Issues Task
Force (EITF) No. 96-18, Accounting for Equity Instruments That Are Issued to
Other Than Employees for Acquiring or in Conjunction With Selling Goods or
Services, and recognized over the related service period. During fiscal 2004,
the Company issued 1,000,000 common stock warrants at an exercise price of $1
per share expiring July 22, 2009. The value of these warrants is being amortized
to expense over their lives using the Black-Scholes pricing model with the
following assumptions: 60 months expected life, 100% stock volatility, 3.625%
risk-free interest rate and no dividends.
NOTE 4 - Loss per Share
In accordance with SFAS No. 128, Earnings per Share, and SEC Staff Accounting
Bulletin (SAB) No. 98, basic net loss per common share is computed by dividing
net loss for the period by the weighted average number of common shares
outstanding during the period. Under SFAS No. 128, diluted net income (loss) per
share is computed by dividing the net income (loss) for the period by the
weighted average number of common and common equivalent shares, such as stock
options and warrants, outstanding during the period. Such common equivalent
shares have not been included in the computation of net loss per share as their
effect would be anti-dilutive.
7
Numerator -Net loss $ ( 1,721,717)
Denominator--Weighted average shares outstanding 17,953,242
Net loss per share $ ( 0.10)
Incremental common shares (excluded from denominator
because they are anti-dilutive) Warrants 1,000,000
NOTE 5- Amounts due to Related Parties
On July 22, 2004, the Company entered into a secured credit facility for $5.0
million with Bioaccelerate which bears interest at 3.625%. The Company intends
to use these funds to develop its lead products. The facility is secured by all
tangible and intangible assets. As an inducement to Bioaccelerate Inc. to
provide the credit facility, the Company issued warrants to purchase 1,000,000
shares of its common stock at an exercise price of $1.00 per share expiring on
July 22, 2009. No value was assigned to these warrants.
At March 31, 2005, the Company owes $2,696,754 to Bioaccelerate under the $5.0
million secured credit facility agreement and $100,000 to Sterling FCS Ltd under
an annual contract for the provision of corporate and financial services at a
cost of $10,000 per month.
NOTE 6 - Commitments and Contingencies
Bioaccelerate entered into various drug development and licensing agreements
with leading medical research, academic and private pharmaceutical companies.
Innovate, as a defined "affiliate" of Bioaccelerate under certain of those
agreements, is already a licensee under the terms of certain of those
agreements. On Mach 16, 2005, Bioaccelerate assigned several of those agreements
to Innovate in order to grant rights to six clinical and up to four pre-clinical
compounds from Bioaccelerate's drug portfolio. The assignments are generally
subject to written consent by the other party to the license agreement, which
consent can not be unreasonably withheld, and in one case payment by
Bioaccelerate of some additional consideration to the other party to the license
agreement. In addition, Innovate is already a party to certain licensing
agreements. In our management estimates these Agreements require a minimum
Company investment of approximately $4.4 million over the next three years , of
which the next twelve months requirement will be approximately $2.2 million
Until Innovate secures additional equity capital or other financing, Innovate is
entirely dependent upon financial support by its major shareholder,
Bioaccelerate, to satisfy these commitments and all of the Company's other
capital requirements. If, at any time, Innovate should have insufficient capital
to satisfy the expenditure requirements under the licensing agreements or its
other capital requirements, the Company's business and prospects could be
materially adversely affected and its rights to develop the compounds covered by
the license agreements could be lost or adversely affected.
The Company leases 200 square feet in each of its office facilities in New York
and London from Bioaccelerate on a month-to-month basis for aggregate monthly
rents of approximately $9,000.
8
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
FORWARD LOOKING STATEMENTS: NO ASSURANCES INTENDED
This Form 10-QSB contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. This filing includes statements regarding our plans,
goals, strategies, intent, beliefs or current expectations. These statements are
expressed in good faith and based upon a reasonable basis when made, but there
can be no assurance that these expectations will be achieved or accomplished.
Sentences in this document containing verbs such as "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect," and the like, and/or future-tense
or conditional constructions ("will," "may," "could," "should," etc.) constitute
forward-looking statements that involve risks and uncertainties. Items
contemplating, or making assumptions about, actual or potential future sales,
market size, collaborations, trends or operating results also constitute such
forward-looking statements.
Although forward-looking statements in this Report on Form 10-QSB reflect the
good faith judgment of management, such statements can only be based on facts
and factors currently known by management. Consequently, forward-looking
statements are inherently subject to risks and uncertainties, and actual results
and outcomes may differ materially from the results and outcomes discussed in,
or anticipated by, the forward-looking statements. Factors that could cause or
contribute to such differences in results and outcomes, include without
limitation, those discussed in our Annual Report on Form 10-KSB for the year
ended December 31, 2004. Readers are urged not to place undue reliance on these
forward-looking statements, which speak only as of the date of this Report. We
undertake no obligation to revise or update any forward-looking statements in
order to reflect any event or circumstance that may arise after the date of this
Report. Readers are urged to carefully review and consider the various
disclosures made by us in our Annual Report on Form 10-KSB for the year ended
December 31, 2004, which attempt to advise interested parties of the risks and
factors that may affect our business, financial condition, results of operation
and cash flows.
The following discussion should be read along with the Consolidated Financial
Statements and Notes to our audited financial statements for the fiscal year
ended December 31, 2004, as well as the other interim unaudited financial
information for the current fiscal year.
Critical Accounting Policies and Estimates
The preparation of the Company's financial statements requires management to
make certain critical accounting estimates that impact the stated amount of
assets and liabilities at a financial statement date and the reported amount of
income and expenses during a reporting period. These accounting estimates are
based on management's judgment and are considered to be critical because of
their significance to the financial statements and the possibility that future
events may differ from current judgments, or that the use of different
assumptions could result in materially different estimates. The critical
accounting policies and estimates have not changed from and should be read in
conjunction with the Company's Annual Report filed on Form 10-K for the year
ended December 31, 2004.
The Company's estimates are reviewed continuously to ensure reasonableness.
However, the amounts the Company may ultimately realize could differ from such
estimated amounts
Overview
Innovate Oncology, Inc. (the "Company" or "Innovate") acquires, develops and
seeks to commercialize novel compounds to treat various types of cancer. Our
drug pipeline consists of eight drug candidates--six in clinical development and
two in pre-clinical development--and focuses on multiple forms of cancer,
including three of the most prevalent: breast, prostate and colon cancer.
Bioaccelerate Holdings, Inc. ("Bioaccelerate") owns 88.6% of the Company's
common stock. Bioaccelerate is a pharmaceutical development company incorporated
in Nevada and traded on the Over-the-Counter Bulletin Board ("OTCBB") under the
symbol OTCBB: BACL. Like the Company, Bioaccelerate enters into co-development
and licensing agreements with leading medical research, academic and private
pharmaceutical companies. On July 21, 2004, Bioaccelerate sold its UK
subsidiary, Innovative Oncology Limited, ("Innovative") to Innovate Oncology,
Inc. ("Innovate Oncology"), a Delaware corporation, in exchange for 100% of the
outstanding common stock of Innovate Oncology. As part of that transaction,
Bioaccelerate agreed to assign the licenses, rights and obligations for six
clinical and up to four pre-clinical drug compounds from its portfolio of drug
candidates in development to Innovate Oncology.
On August 23, 2004, Innovate Oncology entered into an agreement with Hampton
Berkshire Insurance & Financial, Inc. ("Hampton") in which Hampton agreed to
acquire 100% of the outstanding common stock of Innovate Oncology. As part of
the transaction, Hampton, a Nevada corporation, canceled 5,026,590 shares of its
common stock, effected a 3.8-for-1 reverse stock split, which reduced its
pre-acquisition outstanding common stock to 1,453,242, and issued 16,500,000
shares of its common stock to Innovate Oncology's shareholders. Contemporaneous
with the close of the acquisition, the Company changed its corporate name from
Hampton to Innovate Oncology, Inc., moved its corporate office to New York, and
replaced all management, corporate officers and directors. At the close of the
acquisition on October 1, 2004, the Company had 17,953,242 shares of common
stock issued and outstanding.
9
Business Strategy
Large pharmaceutical companies need additional drugs of substantial market
potential to fill depleted development pipelines, particularly since many of
their products will soon be losing patent protection and internal development
may fail to keep up with commercial demand for innovation. Increasingly those
companies seek to fill that gap by in-licensing drugs at the middle to late
stages of development rather than acquiring compounds at an earlier stage.
In-licensed Phase III products accounted for more 30% of the in-licensing
agreements made by large pharmaceutical companies in 2002, according to Reuters
Business Insight.
Innovate uses a broad network of relationships it has forged in academia,
medical research centers and industry to in-license or acquire promising
early-stage compounds and existing compounds that can be reformulated, used for
new indications or used with new dosing regimens. We rely upon these
relationships and a product development network to accelerate the time it takes
for new compounds to reach the critical Phase III clinical trial level when a
drug is most attractive to large pharmaceutical companies.
We enter into development, marketing and partnership agreements with contract
research laboratories, industry experts and pharmaceutical companies to develop,
test and seek regulatory approval for our drug candidates. By relying primarily
upon contracts with third parties for research, clinical development and project
management rather than doing that work in-house, we are able to maintain a
limited and less costly infrastructure, particularly as compared with large
pharmaceutical companies. Our management believes that this streamlined
operating strategy has created an efficient and cost-effective route from
early-stage clinical development to a commercial product.
Product Development
A major element of our product development strategy is the use of third-parties
or Contract Research Organizations ("CRO") for drug development at all stages
along the path to market. CROs conduct safety and efficacy tests and clinical
studies and assist us in guiding products through the Food and Drug
Administration ("FDA") and the European Medicines Agency ("EMEA") regulatory
review and approval processes. The Company also uses the contract manufacturing,
formulation and chemistry skills of external providers.
We believe the use of third-parties to develop and manufacture our products has
several advantages over building a comprehensive infrastructure to handle all
such functions in-house. This approach generally gives us more choice and
greater selectivity in the dedicated resources we will concentrate on a
developing product than if those functions were performed by internal personnel
who were required to support the full range of our product development
activities. We believe that maintaining a limited infrastructure, particularly
focused upon early-stage processes in the drug development path will enable us
to develop products efficiently and cost effectively. Although this approach
will allow us to avoid the expense associated with developing a large internal
infrastructure to support our product development efforts, it also means that we
will continue to be dependent on the ability of outside parties to perform
critical functions for us.
The contract approach to product development requires project management by
professionals with substantial industry experience. We plan to evaluate
prospective additions to our in-house expertise as well as opportunities for
contract and advisory services in areas of critical importance to all of our
proposed products, including the management of current pipeline development
teams. The product development process is designed to identify problems
associated with a proposed product's safety and effectiveness. We also attempt
to reduce the risk that a proposed product will not be accepted in the
marketplace by conducting market research and defining a commercial strategy for
each product candidate. A drug development portfolio cannot be completely
insulated from potential clinical and market failures. It is likely that some
proposed products we select for development will not produce the clinical or
revenue results expected. Additionally, we may choose to license at an early
stage or divest product candidates from our portfolio if they produce clinical
results outside our target sector and/or require financial, development and
management resources better met by larger or more specialized pharmaceutical or
biopharmaceutical companies.
Research and Development
Our primary research and development efforts have focused on identifying
promising compounds and developing them into products to treat various types of
cancer. We engage in research, pre-clinical studies and clinical development
with third-party laboratories, including Supratek Pharma, Inc., Faustus
Forschungs Cie. in Germany, Baylor School of Medicine and Northwestern
University for pre-clinical development; Klinikum Chemnitz gGmbH and Technical
University Munich, both in Germany, for clinical trials; Hesperion Ltd. in
Switzerland for clinical CROs; and Nycomed in Denmark and PMRS, Inc. for drug
substance and product manufacturing. Our research and development structure is
designed to enable us to evaluate and make the best choices for where and how
projects are run and resourced. Each is managed as a discrete project with its
own budget and project management. When it's practical and desirable, different
projects will use common resources and contracted facilities.
10
Our budget projections for research and development are based primarily upon
those established and set out in or pursuant to our agreements with research and
co-development partners. Projects may meet development and regulatory barriers,
however that require additional work or a change in approach which can lead to
changes in both timing and budget requirements to maintain a product's path to
market. When this situation arises we tend to be in a more flexible position to
meet such demands than a fully internally resourced pharmaceutical company that
relies on existing internal capabilities to progress. Innovate Oncology's
Product Portfolio
One in three Americans will be diagnosed with cancer, and two out of three
diagnosed with the disease will die from it, according to Reuters Business
Insight. Our objective is to provide cancer patients with effective and safe
therapeutics that save or prolong their lives. We are developing a diversified
product portfolio targeting multiple forms of cancer, including three of the
most prevalent: breast, prostate and colon cancer. Our pipeline of eight drugs
will consist of six drug candidates in or beginning clinical trials and two in
pre-clinical stages of development. The clinical candidates can be divided into
the following categories: New Chemical Entities ("NCE"), therapeutic switches of
existing drug in the market that are not indicated currently to treat cancer,
and reformulations of drugs in the market indicated to treat cancer.
The portfolio of clinical candidates will include two NCEs, which may have the
greatest commercial potential, but also carry the highest risk precisely because
of their novelty. The portfolio's therapeutic switch offers the advantages of
being a proven drug that we believe may have medical and market value that isn't
realized fully by its current use. Like a therapeutic switch, reformulating an
existing, FDA-approved compound offers lower risk to the Company because it's
less expensive to develop. We also have four compounds in pre-clinical
development. We believe this diversified approach balances the risks and rewards
inherent in each drug candidate and its particular development program.
Our portfolio is characterized by compounds that have multiple mechanisms of
action, which we believe may substantially increase a compound's clinical
efficacy. Also, several of these products are lead compounds derived from novel
technologies with the potential for follow-on compounds to be developed into
separate products for related indications.
Innovate Oncology's Product Pipeline
The table below summarizes the status of our development programs.
- -------------------------------------------------------------------------------------------------------
Phase of Development
-------------------------------------------------------
Product
Candidate Indication Pre-Clinical Phase I Phase II Phase III
- -------------------------------------------------------------------------------------------------------
INOC-001 Chemo-Resistance Inhibitor
INOC-002 Chemotherapy Potentiator
INOC-003 Targeted Ruthenium Complex
INOC-005 Capridine Beta
INOC-009 Oral Paclitaxal Formulation
INOC-010 Polymer-Formulated Camptothecin
INOC-016 HER2 Oncogene Inhibitor
INOC-019 Prostate Tumor Suppressor
"Pre-Clinical" refers to the series of tests in the laboratory and those
performed on animals after a lead molecule has been identified. Basic
pharmacology is completed in this phase as well as the toxicology required for
human testing, which may be ongoing. Primary and secondary manufacturing of the
active compound and the method of drug delivery (intravenous or tablet, for
example) will be established during this time. Testing in humans is expected to
begin within 18 and 24 months. Pre-clinical tests must be completed before an
Investigational New Drug application ("IND") can be submitted to the FDA.
"IND" refers to the preparation of an Investigational New Drug application, the
process by which a drug is submitted to the FDA to receive approval for human
testing.
"Phase I" refers to the stage in which compounds are tested for safety, maximal
tolerated dose and pharmacokinetics in volunteers without the disease.
"Phase II" refers to the initial stages of compound testing in patients with the
disease (a particular indication) or symptoms of interest for ultimate New Drug
Application ("NDA") approval and labeling. This stage first demonstrates the
compound's efficacy and dosing range, and expands the safety profile.
11
"Phase III" refers to the rigorously controlled test of a new drug in a large
population of patients with the disease. After the successful conclusion of
Phase III clinical trials, an NDA is filed with the FDA for approval to market
the drug.
INNOVATE PRODUCTS IN DEVELOPMENT: CLINICAL CANDIDATES
INOC-001 Chemo-resistance Inhibitor
Description . INOC-001 is the lead drug candidate in our portfolio. Our
management believes that the compound offers a novel approach to overcoming
resistance to chemotherapy that many patients develop over the course of
treatment. The compound, which is marketed as an anti-viral drug in Germany and
other European countries, is being tested to treat metastatic pancreatic cancer.
In pre-clinical studies, INOC-001 demonstrated an ability to reduce toxic side
effects, slow disease progression and increase survival rates when used in
conjunction with some chemotherapeutic drugs. Pre-clinical experiments have
shown evidence of INOC-00l inhibiting several genes responsible for
chemo-resistance as well as using multiple mechanisms of action. We have
completed a Phase I trial with various types of solid tumors and chemotherapy
regimens and have documented early efficacy in patients with pancreatic cancer.
Market Opportunity . The American Cancer Society estimates that in 2005, 32,180
people in the U.S. will be diagnosed with pancreatic cancer and 31,800 patients
will die from the disease. The five-year survival rate is only 4.4%, making it
one of the most lethal forms of cancer. Fewer than 10% of patients respond to
treatment.
Partnerships . Cynat Oncology Inc, a wholly owned subsidiary of Bioaccelerate,
is a joint venture partner in Resistys, Inc. with Australian Cancer Technology
("ACT"). As part of Bioaccelerate's obligation to provide six clinical products
to Innovate, Bioaccelerate transferred 100% of the capital stock of Cynat
Oncology Inc to Innovate on March 16, 2005 following an announcement on February
14, 2005, that Bioaccelerate would assign its rights to develop and
commercialize INOC-001 to Innovate. The Company is sharing the development costs
equally with its partner as well as an exclusive license to market the product
in the U.S. and Canada.
Status . On December 15, 2004, Bioaccelerate announced it had initiated a Phase
I/II clinical trial for the treatment of metastatic pancreatic cancer with its
co-development partner ACT. The eight-month study will include 22 patients with
metastatic pancreatic cancer and will be conducted at three leading centers in
Germany: Chemnitz Clinics in collaboration with the Technical University
Dresden; Munich University of Technology's Kilinikum rects der Isar; and
University of Munich Hospital's Klilnikum Gro(beta)hadern. The trial is being
managed by Swiss CRO Hesperion. INOC-001 tablets are administered in conjunction
with conventional chemotherapy agents and will be evaluated in this study with
Gemcitabine. Eight patients have been enrolled and dosed.
Patents . A U.S. patent was granted for the compound in 2003 and another U.S.
patent is pending. A patent was issued under the terms of the Patent Cooperative
Treaty ("PCT"), which is adhered to by more than 100 countries.
INOC-002 Chemotherapy Potentiator
Description . INOC-002 is an enhancement and a new dosing regimen of an
intravenous drug approved to treat colon cancer. The Company intends to test a
novel dosing regimen, administering the drug simultaneously with capecitabine, a
commonly used chemotherapeutic agent. Administering the drugs simultaneously
could make capecitabine more effective, and therefore may permit a lower dose,
which in turn would reduce toxic side effects. The Company believes that current
dosing regimens based on its labeled use as an anti-worming agent have not
optimized the potential synergistic effect of INOC-002 that could be achieved by
combined dosing. The lead indication of INOC-002 is a post-operative adjuvant
therapeutic agent.
Market Opportunity . Colorectal cancer is the third most prevalent form of
cancer globally, according to Reuters Business Insight. Its annual mortality
rate is almost as high as the mortality rates for breast and prostate cancer
patients combined even though the patient population for those two types of
cancer is more than four times the size of the colorectal patient population. In
2003, approximately 889,000 patients were being treated for the disease and
428,000 new patients were diagnosed.
Partnerships . On August 6, 2004, Bioaccelerate entered into an agreement with
Targent, Inc. to acquire eight patents and certain confidential information
related to INOC-002. Bioaccelerate assigned this agreement to Innovate on March
16, 2005 subject to consent by Targent. The agreement between Bioaccelerate and
Targent requires consent by the other perty to any assignment which consent may
not be unreasonably withheld or delayed. Bioaccelerate has sought consent from
Targent to the assignment and is awaiting confirmation by Targent. The Company
is responsible for the drug development costs as well any maintenance fees on
patents and patent applications.
Status . Pre-clinical trials confirmed the additive effect of INOC-002. The
Company plans to apply for an IND in the second quarter of 2005 and begin
clinical efficacy Phase II trials by the end of the year.
Patents . Eight patent applications were filed between December 1, 2000 and
March 15, 2005 for patents in the U.S., Canada, Europe, Australia, Japan, Hong
Kong and an international patent.
12
INOC-003 Targeted Ruthenium Complex
Description. INOC-003 is an NCE being developed to treat various types of
cancer. We believe that this drug's unique mechanism of action involves targeted
accumulation in tumor cells leading to program cell death.
Market Opportunity . In pre-clinical studies, the compound has demonstrated
efficacy in lung, liver and colorectal cancer, among others. While the Company
believes this drug candidate may have the potential to treat several types of
cancer, it intends to test INOC-003 to treat liver cancer, in part because it is
an unmet need. Liver cancer is the third most common cause of death from cancer
globally, accounting for 10.4% of approximately 56 million deaths from cancer in
2000, according to the World Health Organization's World Cancer Report.
Partnerships . On December 14, 2004, Bioaccelerate announced it had entered into
a development agreement with Faustus Forschungs Cie. Translational Cancer
Research GmbH and Faustus Forschung Translation Drug Development AG ("Faustus")
to co-develop eight new anti-cancer drug candidates. Bioaccelerate assigned one
of those candidates, INOC-003, to its subsidiary, Innovate, on March 16, 2005
The Company will fund a three-year development and commercialization plan and,
in consequence will gain the right to market INOC-003 worldwide.
Status . INOC-003 has completed Phase I trials. The Company hopes to launch
Phase II in the second quarter of 2005.
Patents . A European patent has been issued. Nine other patents have been filed
in the U.S., Germany, Europe, Australia, Canada, India, and Japan as well as a
PCT patent.
INOC-005 Capridine Beta
Description. INOC-005 is an NCE to treat prostate cancer. The compound renders
aggressive hormone-independent prostate cells hormone-sensitive and therefore
may be effective in treating both hormone-sensitive and hormone-insensitive
tumors in combination with anti-androgen therapy. In pre-clinical development,
INOC-005 also showed activity against leukemia, melanoma, lung, colon, ovarian,
renal and bladder cancer. Toxicology studies indicate that this compound may
have lower bone marrow toxicity.
Market Opportunity. In 2003, approximately 300,000 men in the seven major market
countries (U.S., France, Germany, Italy, Spain, Japan and the UK) were diagnosed
with prostate cancer; the total patient population was 1,774,000, according to
Reuters Business Insight. Those patients had a 99.7% one-year survival rate and
a 96.8% five-year survival rate. Treatment for prostate cancer is one of the
success stories in oncology research. Nonetheless there's room for improvement
given the prevalence of the disease.
Partnerships . On March 31, 2005, the Company entered into an agreement with
Prostagenics, LLC pursuant to which , Innovate obtained the global patent rights
to develop and commercialize INOC-005.
Status. Pre-clinical development has been completed. The Company expects to file
an IND application in the third quarter of 2005 to conduct Phase I clinical
trials for advanced prostate cancer.
Patents. A U.S. patent was granted to this product candidate in 2003. Seven
other patent applications have been filed for this compound in the U.S., Canada,
Mexico, Europe and Israel.
INOC-009 Oral Paclitaxal
Description. INOC-009 is a reformulation of a commonly used intravenous
chemotherapeutic agent that treats several types of cancer, including breast,
ovarian and AIDS-related Kaposi's sarcoma. This new, oral formulation improves
the drug's solubility and therefore facilitates absorption into the bloodstream.
The formulation also prevents efflux of the drug from the intestine.
Market Opportunity. Breast cancer is the second most common form of cancer
worldwide, according to the World Health Organization's World Cancer Report. An
existing intravenous paclitaxal product (Taxol(R)) was one of the top 10 selling
cancer drugs in 2004 with sales of more than $1.2 billion.
Partnerships . On July 15, 2004, Bioaccelerate entered into a license and
co-marketing agreement with Supratek, Pharma, Inc. to develop INOC 009 to treat
cancer in humans. Innovate is already a licensee under the terms of the
agreement but Bioaccelerate has also assigned its rights under this agreement to
Innovate on March 16, 2005, subject to receipt of Supratek's written consent,
which can not be unreasonably witheld. Bioaccelerate has sought that consent and
is awaiting confirmation by Supratek.
Status . Pre-clinical testing has been completed. The Company expects to file an
IND application with the FDA in the third or fourth quarter of 2005.
13
Patents . Supratek owns a total of four "composition of matter" patents in the
U.S. related to its proprietary technology and is responsible for maintenance
and upkeep of its patents
INOC-010 Polymer-Formulated Camptothecin
Description. INOC-010 is a reformulation that uses an innovative, proprietary
carrier technology to treat drug-resistant tumors. This technology has
demonstrated improved efficacy compared with the previous formulation because it
increases the amount of the drug taken up by tumor cells and inhibits drug
efflux associated with tumor resistance. This intravenous reformulation of
topotecan showed no apparent change in toxicity during pre-clinical tests to
treat melanoma, breast and lung cancer.
Market Opportunity. Topotecan is currently indicated to treat ovarian cancer and
small cell lung cancer.
Partnerships . On November 10, 2004, Bioaccelerate entered into a licensing and
co-marketing agreement with Supratek Pharma, Inc. to develop, seek regulatory
approval and, in major markets, commercialize INOC-010. Supratek granted
Bioaccelerate an exclusive global license to its intellectual property related
to INOC-010. Innovate is also a licensee under the terms of the agreement but
Bioaccelerate has also assigned its rights under this agreement to Innovate on
March 16, 2005, subject to receipt of Supratek's written consent, which consent
can not be unreasonably withheld. Bioaccelerate has sought that consent and is
awaiting confirmation from Supratek.
Status . Pre-clinical testing is complete. The Company expects to file an IND
application with the FDA in the third or fourth quarter of 2005.
Patents. Supratek owns a total four "composition of matter" patents in the U.S.
related to its proprietary technology and is responsible for maintenance and
upkeep of its patents.
PRE-CLINICAL PROJECTS
INOC-016 HER2 Oncogene Inhibitor
Description. INOC-016 is a small molecule that has been shown to inhibit
expression of the HER2 gene that is over expressed in 30% of all breast cancer
tumors and is associated with a poor outcome. Herceptin(R) is a monoclonal
antibody that binds to HER2 on tumor cells. It is currently marketed and
approved for use with chemotherapy to treat advanced breast cancer.
The Company believes that INOC-016, by preventing the expression of the gene,
may lead to a more complete eradication of the HER2 protein and therefore be
more efficacious in the management of breast cancer.
Status. In pre-clinical testing of this drug, INCO-016 has been shown to stop
the growth of breast cancer tumors in animal models.
Partnerships . On January 4, 2005, Bioaccelerate entered into an exclusive
license agreement with Baylor College of Medicine granting Bioaccelerate
worldwide exclusive rights to patents and other intellectual property rights
associated with INOC-016 to develop and commercialize the compound.
Bioaccelerate conditionally assigned this agreement to Innovate on March 16,
2005.
Patents . A U.S. patent application was filed in 2003 and a joint PCT/U.S.
patent application was filed in 2003. Baylor is responsible for filing,
prosecuting and maintaining all patents. The Company will pay all legal costs
associated with these patents.
INOC-019 Prostate Tumor Suppressor
Description. A peptide derived from a novel, proprietary tumor suppressor
protein designed to induce the death of prostate cancer cells in vitro and in
animal models.
Partnerships . On March 15, 2005, Bioaccelerate entered into a license agreement
with Northwestern University. The agreement granted Bioaccelerate an exclusive
global license to the patent rights to develop and commercialize INOC-019.
Bioaccelerate assigned this agreement to Innovate on March 16, 2005.
Patents . A U.S. patent was granted for this compound in 2004.
COMPANY STATUS
The Company continues to make significant progress in developing its product
portfolio, and has multiple products in clinical trials with other compounds
following on in development. We have continued to incur losses as expected
during this emerging stage. We anticipate that the success of our immediate
product development strategy will permit us to further develop our other
products and potential products currently in our portfolio.
14
A major element of the Company's product development strategy has been the use
of third-party or contract research organizations ("CROs") to assist in the
conduct of safety and efficacy testing and clinical studies, to assist the
Company in guiding products through the FDA and EMEA regulatory review and
approval processes, and to manufacture and distribute any FDA and EMEA approved
products. The Company believes that maintaining a limited infrastructure will
enable it to develop products efficiently and cost effectively. However
consideration will be given to opportunities to strengthen the resources and
portfolio in certain areas that may prove viable commercially and add value to
the overall business in the future.
The reader should consider the likelihood of our future success to be highly
speculative in light of our limited operating history, as well as the limited
resources, problems, expenses, risks and complications frequently encountered by
similarly situated companies. To address these risks, we must, among other
things:
o advance our lead product candidates and technology platforms;
o obtain required government and other public and private approvals on
a timely basis;
o enter into corporate partnerships;
o license additional technology;
o maintain a proprietary position in our technologies and products;
and
o attract and retain key personnel.
The Company may not be successful in addressing these risks. If we are unable to
do so, our business prospects, financial condition and results of operations
would be materially adversely affected. The likelihood of our success must be
considered in light of the development cycles of pharmaceutical and
biopharmaceutical products and technologies and the competitive and regulatory
environment in which we operate.
Results of Operations
During the quarter ended March 31, 2005, work continued on the product
development programs as planned and the individual items are detailed below.
General and administrative expenses amounted to $284,370 for the three months
ended March, 31, 2005. Such costs were primarily consulting fees, in particular
for regulatory, licensing and patent advice.
Research and development expenses for the three months ended March 31, 2005,
amounted to $1,437,347.
Liquidity and Capital Resources
A $5million credit facility was agreed with Bioaccelerate on July 22, 2004. The
Company is using these funds to develop its lead products. This investment has
enabled the Company to achieve significant milestones in its lead development
programs. We believe this facility will be sufficient to support our business
plan until longer term financing can be arranged.
Should we come up against any unforeseen problems, the Company will revisit its
budget and adjust the scheduling and costs of the development programs
accordingly to allow the Company to operate until sufficient long term funding
is achieved. However, a key element of our business strategy is to continue to
acquire, obtain licenses for, and develop, new technologies and products that we
believe offer unique market opportunities and/or complement our existing product
lines.
ITEM 3 - CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and Chief Financial Officer have, as of the end of
the period covered by this Report, reviewed our process of gathering, analyzing
and disclosing information that is required to be disclosed in our periodic
reports (and information that, while not required to be disclosed, may bear upon
the decision of management as to what information is required to be disclosed)
under the Exchange Act of 1934, including information pertaining to the
condition of, and material developments with respect to, our business,
operations and finances. Based on this evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that our process provides for timely
collection and evaluation of information that may need to be disclosed to
investors.
15
Changes in Internal Controls Over Financial Reporting
There have been no significant changes in the Company's internal controls over
financial reporting that occurred during the quarter ended March 31, 2005, that
have materially affected, or are reasonably likely to materially affect our
internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may be involved in litigation relating to claims arising
out of our operations in the normal course of business. We currently are not a
party to any legal proceedings, the adverse outcome of which, in management's
opinion, individually or in the aggregate, would have a material adverse effect
on our results of operations or financial position.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5. OTHER INFORMATION
None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8
(a) Exhibits. The following exhibits are filed with this report.
31. Written Statement of Chief Executive Officer and Chief Financial Officer
with respect to compliance with Section 13(a) or 15 (d) of the Securities
Exchange Act of 1934 and Section 302 of the Sarbanes-Oxley Act of 2002.
32. Written Statement of Chief Executive Officer and Chief Financial Officer
with respect to compliance with Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and pursuant to 18 U.S.C. 1350, as adopted pursuant to ss.
906 of the Sarbanes-Oxley Act of 2002.
(b) Reports on Form 8-K. The following reports have been filed on Form 8-K
during the last fiscal quarter:
None
16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned authorized officers.
Dated: May 12, 2005
Innovate Oncology, Inc.
By: /s/ Nigel Rulewski
- ------------------------------------
Nigel Rulewski
CEO, President & Director
(Principal Executive Officer)
By: /s/ Alan Bowen
- ------------------------------------
Alan Bowen
CFO, Secretary, Treasurer & Director
(Principal Financial Officer)
17